Case Reports
doi: 10.1016/j.ygyno.2006.04.025.
Epub 2006 Jun 23.
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma
Affiliations
- PMID: 16797679
- DOI: 10.1016/j.ygyno.2006.04.025
Item in Clipboard
Case Reports
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma
Gynecol Oncol.
2006 Sep.
Abstract
Background: The ongoing search for more effective agents in the treatment of uterine leiomyosarcomas is warranted because of the poor prognosis related to these tumors.
Case: A case of advanced, recurrent and refractory uterine leiomyosarcoma is presented that responded to trabectedin (ET-743) 1.2 mg/m2 intravenously over 24 h every 3 weeks after failing four prior regimens. A durable objective response lasting at least 8 months was documented.
Conclusion: Trabectedin (ET-743) has activity in uterine leiomyosarcoma and warrants further investigation.
Similar articles
-
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.Gynecol Oncol. 2012 Jan;124(1):48-52. doi: 10.1016/j.ygyno.2011.09.019. Epub 2011 Oct 13. Gynecol Oncol. 2012. PMID: 21996263 Free PMC article. Clinical Trial.
-
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.Anticancer Drugs. 2017 Apr;28(4):465-468. doi: 10.1097/CAD.0000000000000485. Anticancer Drugs. 2017. PMID: 28181940
-
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.Gynecol Oncol. 2011 Dec;123(3):553-6. doi: 10.1016/j.ygyno.2011.08.016. Epub 2011 Sep 13. Gynecol Oncol. 2011. PMID: 21917307
-
An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.Int J Gynecol Cancer. 2011 May;21 Suppl 1:S3-5. doi: 10.1097/IGC.0b013e318217b34d. Int J Gynecol Cancer. 2011. PMID: 21540667 Review.
-
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.Oncol Res. 2013;20(10):483-90. doi: 10.3727/096504013x13685487925130. Oncol Res. 2013. PMID: 24308159 Review.
Cited by
-
Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO).Gynecol Oncol Rep. 2020 Jun 4;33:100594. doi: 10.1016/j.gore.2020.100594. eCollection 2020 Aug. Gynecol Oncol Rep. 2020. PMID: 32566719 Free PMC article.
-
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.Br J Cancer. 2018 Aug;119(5):565-571. doi: 10.1038/s41416-018-0190-y. Epub 2018 Jul 30. Br J Cancer. 2018. PMID: 30057406 Free PMC article. Clinical Trial.
-
Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report.Case Rep Oncol. 2018 Feb 9;11(1):81-89. doi: 10.1159/000486638. eCollection 2018 Jan-Apr. Case Rep Oncol. 2018. PMID: 29515415 Free PMC article.
-
Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Eur J Cancer. 2008 Nov;44(16):2357-87. doi: 10.1016/j.ejca.2008.07.001. Epub 2008 Aug 11. Eur J Cancer. 2008. PMID: 18701274 Free PMC article. Review.
-
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.Gynecol Oncol. 2012 Jan;124(1):48-52. doi: 10.1016/j.ygyno.2011.09.019. Epub 2011 Oct 13. Gynecol Oncol. 2012. PMID: 21996263 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
